IVGAX
Price
$22.59
Change
-$0.40 (-1.74%)
Updated
Feb 21 closing price
Net Assets
157.69M
VIVIX
Price
$68.78
Change
-$0.82 (-1.18%)
Updated
Feb 21 closing price
Net Assets
192.55B
Ad is loading...

IVGAX vs VIVIX

Header iconIVGAX vs VIVIX Comparison
Open Charts IVGAX vs VIVIXBanner chart's image
VY® Invesco Growth and Income A
Price$22.59
Change-$0.40 (-1.74%)
VolumeN/A
Net Assets157.69M
Vanguard Value Index I
Price$68.78
Change-$0.82 (-1.18%)
VolumeN/A
Net Assets192.55B
IVGAX vs VIVIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
IVGAX vs. VIVIX commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVGAX is a Hold and VIVIX is a StrongBuy.

Ad is loading...
FUNDAMENTALS
Fundamentals
VIVIX has more cash in the bank: 193B vs. IVGAX (158M). VIVIX pays higher dividends than IVGAX: VIVIX (2.37) vs IVGAX (1.23). IVGAX was incepted earlier than VIVIX: IVGAX (21 years) vs VIVIX (27 years). IVGAX has a lower initial minimum investment than VIVIX: IVGAX (0) vs VIVIX (5000000). VIVIX annual gain was more profitable for investors over the last year : 13.44 vs. IVGAX (2.77). VIVIX return over 5 years is better than : 47.20 vs. IVGAX (7.43).
IVGAXVIVIXIVGAX / VIVIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence21 years27 years-
Gain YTD3.7674.16590%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets158M193B0%
Annual Yield % from dividends1.232.3752%
Returns for 1 year2.7713.4421%
Returns for 3 years-10.2123.92-43%
Returns for 5 years7.4347.2016%
Returns for 10 years-16.60105.52-16%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EWBC93.89-3.23
-3.33%
East West Bancorp
SIGA5.91-0.22
-3.51%
SIGA Technologies
INTA66.11-3.25
-4.69%
Intapp
BMEA3.46-0.19
-5.21%
Biomea Fusion
CNSP3.23-0.52
-13.87%
CNS Pharmaceuticals Inc.